Xolair

Lea en español

Xolair
Xolair (the trade name for Omalizumab), is a drug that has been approved to treat teenagers and adults with severe allergic asthma since its introduction in Australia in 2002. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it has been held out as being particularly effective for people who cannot be treated with H1 antihistamines or do not benefit from high doses of corticosteroids. It has also been used to treat people who suffer chronically from hives.

A number of adverse side effects have been linked to the use of Xolair, including:

  • Anaphylactic shock or anaphylaxis (a life-threatening allergic reaction)
  • Increased risk of heart disease
  • Increased risk of stroke
  • Masking of warning signs of certain cancers

If you or someone you love has suffered injury after being prescribed Xolair, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

Happy 4th of July

Our country is not the only thing to which we owe our allegiance. It is also owed to justice and to…

02 Jul 2020, Thursday

Supreme Court Issues Landmark LGBT Employment Law Ruling

Decision Applies Civil Rights Act to Employment Issues in All 50 States The United States Supreme Co…

25 Jun 2020, Thursday

President Seeks to Limit Liability of Meat Companies for COVID-19

Industry Continues to Be Hotspot for COVID Infection State health officials in Idaho announced on Tu…

09 Jun 2020, Tuesday